Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VYVGART Hytrulo in Stiff Person Syndrome (SPS)
NCT07860021Phase 3Recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant human hyaluronidase PH20 in stiff person syndrome (SPS) (2 arms), sponsored by Thomas Jefferson University. Primary endpoint: Stiffness Index at 2 years. Started Sep 2026; status: recruiting.
02
Drugs
recombinant human hyaluronidase PH20
03
Conditions
stiff person syndrome (SPS)
Beyond the preview
Go deeper on NCT07860021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07860021.